Abstract
Sporadic inclusion body myositis (sIBM) is an autoimmune condition that is characterized by progressive weakness and muscular atrophy in the extremities. The pathophysiology is not exactly clear; however, some studies have postulated an involvement of cytotoxic T cells (CD8+), causing an autoimmune response. While the implications of COVID-19 infection are an evolving topic, myositis has been previously implicated in other viral etiologies. We discuss a case of sIBM secondary to COVID-19 in a patient with chronic myalgias bringing to light a rare implication of COVID-19 to educate the medical community.